1-2 of 2
Anne Rafowicz, MD
Close
Sort by
Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Maria Elisa Mancuso, MD PhD, Kathelijn Fischer, MD PhD MSc, Elena Santagostino, MD PhD, Johannes Oldenburg, Prof, Helen Platokouki, MD, Christoph Königs, MD PhD, Carmen Escuriola, MD, Georges-Etienne Rivard, MD, Ana Cid, MD, Manuel Carcao, MD, Rolf Ljung, MD PhD, Pia Petrini, MD, Anne Rafowicz, MD, Carmen Altisent, MD, Gili Kenet, MD, Raina Liesner, Karin Kurnik, MD, Christel Van Geet, MD PhD, Teresa Alvarez-Roman, MD, Tin Tin Yee, MD, Guenter Auerswald, Sr., MD, Rosario Perez-Garrido, MD, Beatrice Nolan, Hervé Chambost, Anne Makipernaa, MD, Angelo Claudio Molinari, MD, Angela Thomas, MBBS, PhD, Elizabeth Chalmers, MD, Mike Williams, MD, Rainer Kobelt, MD, Marijke Van den Berg, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3774.
https://doi.org/10.1182/blood.V128.22.3774.3774
Published: 2016
Journal Articles

Immune Tolerance Resulting in a Dramatic Clinical Improvement in a High-Responding Inhibitor Hemophilia A Patient Using Immunosuppression with Mycofenolate Mofetil and a Factor VIII Concentrate Containing Von Willebrand Factor.

Thierry Lambert, MD, Cécile Goujard, MD, Anne Rafowicz, MD, Benoît Guillet, MD, Yacine Taoufik, MD, Marie Dreyfus
Journal: Blood
Blood (2005) 106 (11): 3220.
https://doi.org/10.1182/blood.V106.11.3220.3220
Published: 2005